|
== Mekanisme kerja ==
Dugaan mekanisme kerja obat ini adalah dengan penghambatan selektif polimerase RNA dependen RNA dari virus.<ref>{{Cite journal|year=2013|title=The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase|journal=PLOS ONE|volume=8|issue=7|pages=e68347|bibcode=2013PLoSO...868347J|doi=10.1371/journal.pone.0068347|pmc=3707847|pmid=23874596|vauthors=Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J}}</ref> Penelitian lain menunjukkan bahwa favipiravir menrangsang mutasi transversi RNA yang mematikan bagi virus.<ref>{{Cite journal|date=April 2013|title=T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro|journal=Journal of Virology|volume=87|issue=7|pages=3741–51|doi=10.1128/JVI.02346-12|pmc=3624194|pmid=23325689|vauthors=Baranovich T, Wong SS, Armstrong J, Marjuki H, Webby RJ, Webster RG, Govorkova EA}}</ref> Favipiravir merupakan [[bakal obat]] yang harus melewati proses metabolisme sebelum dapat memberikan efek antivirus. Metabolit tersebut adalah favipiravir-ribofuranosil-5'-trifosfat (favipiravir-RTP). FavipiravitFavipiravir tersedia dalam bentuk tablet dan injeksi intravena.<ref>{{Cite journal|displayauthors=6|date=Maret 2018|title=Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques|journal=PLoS Medicine|volume=15|issue=3|pages=e1002535|doi=10.1371/journal.pmed.1002535|pmc=5870946|pmid=29584730|vauthors=Guedj J, Piorkowski G, Jacquot F, Madelain V, Nguyen TH, Rodallec A, Gunther S, Carbonnelle C, Mentré F, Raoul H, de Lamballerie X}}</ref><ref>{{Cite journal|date=Oktober 2009|title=Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells|journal=The Journal of Antimicrobial Chemotherapy|volume=64|issue=4|pages=741–46|doi=10.1093/jac/dkp274|pmc=2740635|pmid=19643775|vauthors=Smee DF, Hurst BL, Egawa H, Takahashi K, Kadota T, Furuta Y}}</ref> Hipoxantin guanin fosforibosiltransferase (HGPRT) diyakini memegang peran utama dalam proses metabolisme.<ref>{{Cite journal|date=Oktober 2013|title=Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir)|journal=Molecular Pharmacology|volume=84|issue=4|pages=615–29|doi=10.1124/mol.113.087247|pmid=23907213|vauthors=Naesens L, Guddat LW, Keough DT, van Kuilenburg AB, Meijer J, Vande Voorde J, Balzarini J}}</ref> Favipiravir tidak menghambat sintesis RNA atau DNA dalam sel mamalia, sehingga tidak berbahaya bagi manusia.<ref name="Furuta">{{Cite journal|date=Juni 2009|title=T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections|journal=Antiviral Research|volume=82|issue=3|pages=95–102|doi=10.1016/j.antiviral.2009.02.198|pmc=|pmid=19428599|vauthors=Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD}}</ref> Pada tahun 2014, favipiravir mendapat izin edar di Jepang untuk persediaan obat jika terjadi [[pandemi influenza]].<ref>{{Cite news|url=https://www.bloomberg.com/news/2014-08-07/ebola-drug-from-japan-may-emerge-among-key-candidates.html|title=Ebola Drug From Japan May Emerge Among Key Candidates|date=7 Agustus 2014|publisher=Bloomberg.com|first=Cynthia|last=Koons}}</ref> Namun, favipiravir belum terbukti efektif pada sel di saluran pernapasan, sehingga terdapat keraguan mengenai efektivitas dalam pengobatan influenza.<ref>{{Cite journal|displayauthors=6|date=Agustus 2018|title=Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses|journal=Antimicrobial Agents and Chemotherapy|volume=62|issue=8|pages=e00766–18|doi=10.1128/AAC.00766-18|pmc=6105843|pmid=29891600|vauthors=Yoon JJ, Toots M, Lee S, Lee ME, Ludeke B, Luczo JM, Ganti K, Cox RM, Sticher ZM, Edpuganti V, Mitchell DG, Lockwood MA, Kolykhalov AA, Greninger AL, Moore ML, Painter GR, Lowen AC, Tompkins SM, Fearns R, Natchus MG, Plemper RK}}</ref>
== Status persetujuan ==
|
